Illumina (ILMN) Earning Somewhat Positive Press Coverage, Accern Reports

News articles about Illumina (NASDAQ:ILMN) have been trending somewhat positive on Sunday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Illumina earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news stories about the life sciences company an impact score of 45.5276257232411 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:

A number of equities analysts have recently weighed in on ILMN shares. Argus upped their price objective on Illumina from $205.00 to $235.00 and gave the stock a “buy” rating in a research note on Wednesday, September 13th. Leerink Swann reaffirmed an “outperform” rating and issued a $225.00 price objective (up previously from $207.00) on shares of Illumina in a research note on Tuesday, September 12th. Robert W. Baird raised Illumina from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $184.00 to $228.00 in a research note on Wednesday, October 25th. Wells Fargo & Company reaffirmed a “market perform” rating and issued a $205.00 price objective (up previously from $200.00) on shares of Illumina in a research note on Wednesday, October 25th. Finally, Bank of America Corporation upped their price objective on Illumina from $215.00 to $240.00 and gave the stock a “buy” rating in a research note on Wednesday, October 25th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and thirteen have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of $200.88.

Shares of Illumina (NASDAQ ILMN) opened at $209.02 on Friday. Illumina has a 52-week low of $119.37 and a 52-week high of $214.50. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. The stock has a market capitalization of $30,516.92, a P/E ratio of 61.12, a price-to-earnings-growth ratio of 3.45 and a beta of 0.74.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The business had revenue of $714.00 million for the quarter, compared to the consensus estimate of $692.77 million. During the same period in the prior year, the business posted $0.97 earnings per share. The company’s quarterly revenue was up 17.6% compared to the same quarter last year. equities research analysts predict that Illumina will post 3.75 EPS for the current year.

In other Illumina news, SVP Charles Dadswell sold 145 shares of the company’s stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $205.71, for a total transaction of $29,827.95. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, SVP Oene Mark Van sold 1,250 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The shares were sold at an average price of $207.76, for a total value of $259,700.00. Following the sale, the senior vice president now owns 11,691 shares in the company, valued at $2,428,922.16. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 172,446 shares of company stock worth $35,486,114. Company insiders own 1.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://ledgergazette.com/2017/11/19/illumina-ilmn-earning-somewhat-positive-press-coverage-accern-reports.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply